Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

20 Jul 2005 08:30

Angle PLC20 July 2005 For Immediate Release 20 July 2005 ANGLE plc Wins Contract With The BioBusiness Alliance of Minnesota ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce that its US Consulting and Management division has won acontract with The BioBusiness Alliance of Minnesota, worth $200,000, to conducta comprehensive assessment of the state's biobusiness capabilities. The BioBusiness Alliance of Minnesota is an industry-driven, businessdevelopment organisation of representatives from established and emergingMinnesota companies, universities and government. It is devoted to building thebioscience industry, retaining and creating jobs and economic growth, andpositioning Minnesota as a global leader in biobusiness. The Minnesotabiobusiness industry includes many World-class businesses and institutions suchMedtronic, 3M and the Mayo Clinic. The information from the six month assessment, which will conclude in the fourthquarter of 2005, will benchmark Minnesota against other countries and states.The outcome of the process will identify the State's strengths and developmentneeds, and provide recommendations to target specific areas of biobusiness inwhich Minnesota can compete as a global leader. These recommendations willreflect the convergence of technologies, products, and markets that exist in theState, and identify Minnesota's opportunity areas for growth. ANGLE established a Minnesota office in August 2004 in recognition of thesignificant business potential it believes exists in this State. ANGLE waschosen following a rigorous national and international selection process. ANGLEwas selected for their significant experience both in conducting assessments inthe U.S. and internationally, and for their consulting expertise in thetechnology industry. Dr. Gary P. Evans, CEO of ANGLE's US Operations, said: "We are delighted that ANGLE has been selected to deliver this innovative,industry-driven assessment of Minnesota's biobusiness capabilities. We lookforward to working with the BioBusiness Alliance team to take the first step inthe long-term planning and development of a biobusiness strategy for Minnesota." Andrew Newland, Chief Executive of ANGLE plc, said: "This contract is a great example of ANGLE's continuing expansion within theUnited States. The Minnesota region is a prosperous biobusiness arena and thiscontract will position ANGLE alongside some of the biggest names in the market.We expect that Minnesota will emerge as a further key platform for our Venturesbusiness in the US." - ENDS - For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44(0)1483 295830Lisa Smith, Principal Executive, US Operations Tel: +1 301 524 5654 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This includes extensiveexpertise in the commercialization of technology, new company formation,investment and corporate finance, Research Park and incubator development andmanagement, and delivery of economic development programs. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.